Oncternal Therapeutics In... (ONCT)
| Bid | n/a |
| Market Cap | 1.56M |
| Revenue (ttm) | 1.67M |
| Net Income (ttm) | -34.57M |
| EPS (ttm) | -11.69 |
| PE Ratio (ttm) | -0.05 |
| Forward PE | -0.12 |
| Analyst | n/a |
| Ask | n/a |
| Volume | 644,135 |
| Avg. Volume (20D) | 140,325 |
| Open | 0.70 |
| Previous Close | 0.69 |
| Day's Range | 0.53 - 0.70 |
| 52-Week Range | 0.53 - 13.20 |
| Beta | 1.36 |
About ONCT
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is al...
6 months ago · seekingalpha.com
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call TranscriptOncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President and Chief Executiv...
9 months ago · seekingalpha.com
Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call TranscriptOncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q1 2024 Earnings Call Transcript May 9, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji ...
12 months ago · seekingalpha.com
Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call TranscriptOncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q4 2023 Results Conference Call March 7, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji...
